Silence Therapeutics plc (SLN) stock: key figures, P/E, revenue and dividend
Health Care · ISIN US82686Q1013
Silence Therapeutics plc financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 559,000.00 USD |
| Gross profit | 344,000.00 USD |
| Operating income | -91.08 m USD |
| EBIT | -88.60 m USD |
| Net income | -88.61 m USD |
| Diluted EPS – continuing operations | -0.63 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
More stocks
- CJ Corp 4P Pref (00104K.KS)
- Iwatani Corp (8088.T)
- China Southern Power Grid Energy Efficiency & Clean Energy Co Ltd (003035.SZ)
- Derwent London PLC (DLN.L)
- Hilton Grand Vacations Inc. (HGV)
- PEABODY ENERGY CORP (BTU)
- People.Cn Co Ltd (603000.SS)
- Leyard Optoelectronic (300296.SZ)
- Shanghai Bairun Flavor & Fragrance Co Ltd (002568.SZ)
- Greenland Holdings Corp Ltd (600606.SS)
- Shurgard Self Storage SA (SHUR.BR)
- Hangzhou Cable (603618.SS)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.